Contrast-induced nephropathy (CIN) is a leading cause of hospital-acquired acute kidney injury (AKI). N-acetylcysteine (NAC) was proposed as an effective preventative measure. As data in relation to the use of NAC for the prevention of CIN in peripheral angiography are lacking, a systematic review and meta-analysis were undertaken. A comprehensive search for the published and unpublished data was performed. Data were extracted from the eligible studies. Pooled odds ratios (ORs) were used to calculate the effect of NAC on CIN incidence. Pooled effect size estimates were used to calculate the effect of NAC on serum creatinine (SCr) postcontrast. Our results showed that NAC did not reduce CIN incidence (pooled OR 1.05; 95% confidence interval [CI] 0.38-2.88; P = .92) or the mean SCr levels (pooled weighted mean difference, 4.38; 95% CI 10.4-1.65; P = .15). In conclusion, insufficient evidence exists to recommend NAC for the prevention of CIN in patients undergoing peripheral angiography.
TublinMEMurphyMETesslerFN. Current concepts in contrast media-induced nephropathy. AJR Am J Roentgenol. 1998;171(4):933–939.
2.
NashKHafeezAHouS. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–936.
3.
LevyEMViscoliCMHorwitzRI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996;275(19):1489–1494.
4.
MarenziGLauriGAssanelliE. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780–1785.
5.
GrubergLMintzGSMehranR. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36(5):1542–1548.
KatzbergRWHallerC.Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl. 2006;(100):S3–S7.
8.
AsifAEpsteinM. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 2004;44(1):12–24.
9.
SudarskyDNikolskyE. Contrast-induced nephropathy in interventional cardiology. Int J Nephrol Renovasc Dis. 2011;4:85–99.
10.
AlnaebMEYoussefFMikhailidisDPHamiltonG. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57(1):65–71.
11.
YoussefFGuptaPSeifalianAMMyintFMikhailidisDPHamiltonG. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004;55(1):53–62.
12.
OzhanHErdenIOrduS. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61(7):711–714.
13.
JoSHKooBKParkJS. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. Am Heart J. 2008;155(3):499 e1–e8.
14.
SadatUWalshSRNordenAGGillardJHBoyleJR. Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology. 2011;62(3):225–230.
15.
Al-DelaimyWKMerchantATRimmEBWillettWCStampferMJHuFB. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med. 2004;116(4):236–240.
16.
ParaskevasKIGiannoukasADMikhailidisDP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg. 2009;23(5):690–699.
17.
DerSimonianRLairdN. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
18.
LawlorDKMoistLDeRoseG. Prevention of contrast-induced nephropathy in vascular surgery patients. Ann Vasc Surg. 2007;21(5):593–597.
19.
RashidSTSalmanMMyintF. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40(6):1136–1141.
20.
SandhuCBelliAMOliveiraDB. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity. Cardiovasc Intervent Radiol. 2006;29(3):344–347.
21.
Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250–1259.
22.
KotlyarEKeoghAMThavapalachandranS. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial. Heart Lung Circ. 2005;14(4):245–251.
23.
BriguoriCManganelliFScarpatoP. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2):298–303.
DurhamJDCaputoCDokkoJ. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62(6):2202–2207.
26.
ShahSJHsuCY. Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study. Am J Med. 2004;117(12):948–952.
27.
CoyleLCRodriguezAJeschkeRESimon-LeeAAbbottKCTaylorAJ.Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J. 2006;151(5):1032.e9–1032.e12.
28.
WebbJGPateGEHumphriesKH. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148(3):422–429.
29.
KshirsagarAVPooleCMottlA. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15(3):761–769.
30.
FishbaneS. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008;3(1):281–287.
31.
PannuNMannsBLeeHTonelliM. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65(4):1366–1374.
32.
ZaglerAAzadpourMMercadoCHennekensCH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151(1):140–145.
33.
ShyuKGChengJJKuanP. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40(8):1383–1388.
34.
KayJChowWHChanTM. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289(5):553–558.
35.
BriguoriCColomboAAiroldiF. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2004;44(4):762–765.
36.
Diaz-SandovalLJKosowskyBDLosordoDW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89(3):356–358.
37.
TepelMvan der GietMSchwarzfeldCLauferULiermannDZidekW. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180–184.
38.
MarenziGAssanelliEMaranaI. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354(26):2773–2782.
39.
BriguoriCColomboAViolanteA. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25(3):206–211.
40.
AlonsoALauJJaberBLWeintraubASarnakMJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis. 2004;43(1):1–9.
41.
BirckRKrzossokSMarkowetzFSchnullePvan der WoudeFJBraunC. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362(9384):598–603.
42.
LiuRNairDIxJMooreDHBentS.N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med. 2005;20(2):193–200.
43.
NallamothuBKShojaniaKGSaintS. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117(12):938–947.
44.
DetrenisSMeschiMMusiniSSavazziG. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005;20(8):1542–1550.
45.
Raposeiras-RoubinSAguiar-SoutoPBarreiro-PardalC. GRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function [published online February 01, 2012]. Angiology.
46.
MarenziGAssanelliECampodonicoJ. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150(3):170–177.
47.
StaculFvan der MolenAJReimerP. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21(12):2527–2541.
48.
ShakerOGEl-ShehabyAEl-KhatibM. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. 2010;61(8):731–736.
49.
FillerGBokenkampAHofmannWLe BriconTMartinez-BruCGrubbA. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2005;38(1):1–8.
50.
IshibashiYYamauchiMMushaHMikamiTKawasakiKMiyakeF. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology. 2010;61(8):724–730.
51.
KDIGO. KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1).
